Browsing Tag

DLL3

Harpoon Therapeutics and Roche to Collaborate on Clinical Trials to Study Novel…

Dustin Moskovitz May 2, 2022 0

SOUTH SAN FRANCISCO, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today…

Health

Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and…

Eli Pacheco Jun 5, 2021 0

Three TriTAC clinical programs (HPN424, HPN536 and HPN328) have shown tumor size reductions or stable disease, and meaningful treatment durationAll four clinical programs demonstrate…